Foscarnet Therapy Safety and Efficacy in First Episode CMV-Retinitis in AIDS Patients
Foscarnet sodium
Blood-Borne Infections+24
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
This study focuses on AIDS patients who are dealing with their first episode of cytomegalovirus (CMV) retinitis, an eye infection caused by the CMV virus. The main goal is to assess the safety and effectiveness of a drug called foscarnet as a treatment for this condition. The study also aims to find the best way to administer foscarnet for ongoing treatment. Additionally, the study will look into how foscarnet interacts with another drug, zidovudine (AZT), commonly used in AIDS treatment. During the study, participants will receive foscarnet as their initial treatment. After this, they will be given different maintenance therapy plans with foscarnet. The study will monitor how well the participants respond to these treatments and check for any side effects. It will also examine how the body processes foscarnet when it's taken alone or with zidovudine (AZT).
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Foscarnet Research Program / Park Plaza Hosp
Houston, United StatesOpen Foscarnet Research Program / Park Plaza Hosp in Google Maps